HEALTH DESK
The FDA has approved the combination of lazertinib (Lazcluze) and amivantamab-vmjw (Rybrevant) for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations—exon 19 deletions or exon 21 L858R substitutions. Developed by Janssen Biotech, this targeted therapy offers a personalized treatment approach for eligible patients, aiming to improve outcomes by addressing cancer-driving mutations in NSCLC.